Connor, Clark & Lunn Investment Management (CC&L)’s Organogenesis Holdings ORGO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-71,070	Closed	-$368K	–	1710
2025 Q4	$368K	Sell	71,070 -357,764	-83%	-$1.73M	﹤0.01%	1359
2025 Q3	$1.81M	Sell	428,834 -164,399	-28%	-$764K	0.01%	883
2025 Q2	$2.17M	Sell	593,233 -74,296	-11%	-$277K	0.01%	831
2025 Q1	$2.88M	Buy	667,529 +208,038	+45%	+$840K	0.01%	635
2024 Q4	$1.47M	Sell	459,491 -11,749	-2%	-$39.4K	0.01%	816
2024 Q3	$1.35M	Buy	471,240 +24,878	+6%	+$69.8K	0.01%	787
2024 Q2	$1.25M	Buy	446,362 +19,158	+4%	+$51.4K	0.01%	797
2024 Q1	$1.21M	Buy	427,204 +62,676	+17%	+$213K	0.01%	827
2023 Q4	$1.49M	Buy	364,528 +51,298	+16%	+$144K	0.01%	744
2023 Q3	$996K	Sell	313,230 -82,280	-21%	-$261K	0.01%	821
2023 Q2	$1.31M	Buy	395,510 +102,198	+35%	+$302K	0.01%	715
2023 Q1	$625K	Buy	293,312 +251,789	+606%	+$622K	﹤0.01%	825
2022 Q4	$112K	Buy	+41,523	New	+$121K	﹤0.01%	1104

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ORGO Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Organogenesis Holdings (ORGO) in Q1 2026, closing a stake of 71,070 shares — an estimated $368K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ORGO in Q4 2022 and held it in 13 quarters. The position peaked at $2.88M in Q1 2025. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Organogenesis Holdings position as of Q1 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 71,070 Organogenesis Holdings shares in Q1 2026, an estimated $368K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Organogenesis Holdings in Q4 2022 and held it in 13 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Organogenesis Holdings position peaked at $2.88M in Q1 2025.
121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.